 WOBURN, Mass., March 11, 2021 GLOBE NEWSWIRE -- Replimune Group, Inc. Nasdaq: REPL, a biotechnology company developing oncolytic immuno-gene therapies derived from its ImmulyticTM platform, today announced two poster presentations at the upcoming American Association for Cancer Research AACR Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021. 